aon glp 1 study Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes Amgen Partnership Expands GLP-1 Insurance

A phase 2 trial of semaglutide 2.4 mg in 71 cirrhotic patients confirmed an acceptable safety profile without significant decompensation events, although the primary histological endpoint was not met, possibly due to the limited ability of antifibrotic remodeling to achieve biopsy-detectable fibrosis stage improvement in established cirrhosis over 48 weeks [46]

After that, use sunscreen and gentle care every day to keep the progress going

doi:10.1016/0168-9452(86)90016-6

[DOI] [PubMed] [Google Scholar] 76.Ristic A.J., Savic D., Sokic D., Bogdanovic Pristov J., Nestorov J., Bascarevic V., Raicevic S., Savic S., Spasojevic I

Last updated July 14, 2026 Key takeaways The current FDA Wegovy label, revised February 2026, gives injectable semaglutide an elimination half-life of approximately 1 week

We don't publish dosing or protocols here on purpose those are individualized clinical decisions, made and monitored with you, never copied off a website